Why Asthma Research Matters Right Now
The CDC estimates that over 20 million adults in the U.S. currently have asthma, a number that has climbed steadily over the past two decades. In 2023, the prevalence of current asthma was highest among adults living below the poverty threshold, at 12.5%. State-level data from 2022 showed estimates ranging from 6.8% in Guam to 13.7% in Maine. Those figures translate into missed workdays, emergency department visits, and for some, a persistent sense that their lungs are not entirely their own.
What makes asthma particularly frustrating is its variability. Two people with the same diagnosis can have completely different triggers, symptom patterns, and responses to treatment. This heterogeneity is why asthma research studies continue to multiply — the one-size-fits-all approach simply does not work for a condition this complex.
The research landscape has shifted dramatically in recent years, particularly with the rise of biologics. Monoclonal antibodies targeting specific inflammatory pathways — such as anti-IL-5, anti-IL-4/IL-13, and anti-TSLP agents — have opened doors for patients with severe eosinophilic asthma who previously cycled through oral corticosteroids with limited success and significant side effects. According to a perspective published in BMJ Open Respiratory Research in July 2026, the new NICE guidance on dupilumab for COPD is already prompting discussions about how monoclonal antibody therapy pathways might evolve for patients with overlapping asthma and COPD.
Types of Asthma Clinical Trials
Understanding the different categories of trials can make the search for the right one far less overwhelming.
Phase 1 trials focus on safety. They involve a small group of participants, often healthy volunteers, and ask a basic question: is this compound safe for humans at various doses? A recent example is the study of PRA-216, an investigational drug being tested first in healthy participants and then in those with mild-to-moderate asthma, with enrollment estimated at 96 participants across multiple phases.
Phase 2 trials expand the scope. Dosing is refined, and researchers begin to look for signals of efficacy. This is often where patients with the target condition first enter the picture. A Phase 2B trial of rademikibart for moderate-to-severe uncontrolled asthma, published in the American Journal of Respiratory and Critical Care Medicine in 2025, represents the kind of work happening at this stage.
Phase 3 trials are the large, pivotal studies that can lead to FDA submission. These often enroll hundreds or thousands of participants across dozens of sites. A current Phase 3 trial in Tucson, Arizona, for example, is evaluating a fluticasone propionate/albuterol sulfate combination inhaler in participants aged 12 and older, with 724 participants across multiple locations.
Phase 4 trials, also called post-marketing studies, examine how approved drugs perform in real-world settings. The VESTIGE trial, published in The Lancet Respiratory Medicine in 2025, looked at dupilumab's effect on exhaled nitric oxide and mucus plugs in patients with type 2 asthma — the kind of nuanced question that only becomes relevant after a drug is already on the market.
| Trial Phase | Primary Goal | Typical Participants | Duration | Key Consideration |
|---|
| Phase 1 | Safety and dosing | 20-100 healthy volunteers or patients | Several months | Highest uncertainty; compensation often available |
| Phase 2 | Efficacy signals and side effects | 100-300 patients with the condition | Several months to 2 years | First chance to receive the experimental drug for many conditions |
| Phase 3 | Confirm efficacy, monitor adverse events | 300-3,000+ patients across multiple sites | 1-4 years | Closest to proving whether a treatment works |
| Phase 4 | Long-term safety, real-world use | Varies widely | Months to years | Drug is already approved; lower risk |
Finding the Right Trial
The most direct route to finding asthma clinical trials near me is ClinicalTrials.gov, a database maintained by the National Library of Medicine. The search tool allows filtering by condition, location, phase, and recruitment status. For those less comfortable navigating government databases, the American Lung Association maintains a listing of clinical trials through its Airways Clinical Research Centers, with locations in Arizona, Illinois, New York, North Carolina, and Vermont.
The Trial of Roflumilast in Asthma Management (TRIM), for instance, is recruiting men and women aged 18 and older with poorly controlled asthma and an elevated BMI at five ALA ACRC clinical centers. Contact information for each site is publicly listed, and a phone call is often all it takes to start the screening process.
Regional options exist beyond the major academic centers. In Tucson, Arizona, two actively recruiting asthma studies are enrolling as of August 2026 — one evaluating benralizumab as an add-on therapy for uncontrolled eosinophilic asthma and another testing the fluticasone/albuterol combination inhaler. The Midwest Allergy Sinus Asthma group is running a Phase 4 study for adolescents and adults aged 12 to 80 with uncontrolled asthma, with study-related procedures and medication covered at no cost to participants.
Patients should know that trials have strict eligibility criteria. Age, asthma severity, smoking history, lung function measurements, and current medication regimens all factor into whether someone qualifies. A trial might require a documented diagnosis for at least one year, specific FEV1 values, or a history of exacerbations despite standard therapy. Being screened out of one study does not mean being screened out of all of them, and research coordinators can sometimes suggest alternatives.
The Realities of Participation
One of the most common questions about asthma clinical trials is what participation actually costs. The short answer is that the investigational drug and study-related procedures are generally provided at no charge to participants. Many trials also offer compensation for time and travel. Compensation amounts vary considerably. The Brigham and Women's Hospital Asthma Research Center has offered up to $3,900 for participants who complete 26 onsite visits over a 22-month period, with additional payment for screening visits. Clinical Research of West Florida offers up to $1,100 for asthma clinical trials, and the University of Wisconsin has provided up to $1,350 for asthma research participation. These figures reflect the time commitment involved — clinical trials are not brief surveys but extended engagements with multiple visits, health assessments, and documentation.
Sarah, a 47-year-old teacher from Illinois, enrolled in a severe asthma clinical trial after years of oral prednisone cycles left her with weight gain and bone density concerns. "I was nervous about being in the placebo group," she said, "but the study coordinator walked me through the exact probability, which was one in four. The monitoring alone — monthly lung function tests, blood work, and an asthma specialist checking in — was more attention than I had gotten in years." She completed the 18-month study and, regardless of whether she received the active drug, gained a clearer picture of her asthma triggers and baseline lung function.
The placebo question is worth addressing directly. Many asthma trials are randomized and double-blind, meaning neither the participant nor the research team knows who is receiving the experimental treatment and who is receiving a placebo or standard-of-care comparison. This design is essential for generating reliable data, but it does mean some participants will not receive the active drug. However, most asthma trials are add-on studies, meaning participants continue their existing controller medications throughout the trial. The experimental treatment is layered on top of standard care, not substituted for it.
Steps to Take Before Enrolling
Start by talking to your current pulmonologist or allergist. They can assess whether your asthma is truly uncontrolled on your current regimen and whether a trial makes clinical sense. Some physicians are principal investigators themselves or have colleagues running studies.
Ask the research coordinator pointed questions during the screening visit. What is the purpose of the trial? How many visits are required, and where? What happens if your asthma worsens during the study? Is there a placebo group, and if so, what are the odds of being assigned to it? What is the protocol for managing exacerbations? Can you withdraw at any time, and what does that process look like?
Review the informed consent document carefully. It should outline every procedure, every risk, and every responsibility. Do not sign it until you understand it fully, and bring a family member or friend to the consent discussion if that helps.
Consider the logistics. A trial based at a university hospital an hour from home might be manageable for monthly visits, but weekly visits could become burdensome. Some trials offer travel reimbursement or even lodging for participants who live far from the study site, but this varies.
Check ClinicalTrials.gov for the study's record. Every registered trial has a unique NCT number, and the record includes the study design, eligibility criteria, locations, and contact information. It also shows whether results have been posted, which is useful for understanding the track record of the sponsor or the research group.
For those in urban areas with high asthma prevalence, such as Chicago, New York, or Tucson, multiple trials may be recruiting simultaneously. The Childhood Asthma in Urban Settings (CAUSE) initiative from NIAID has run several studies examining how environmental exposures — cockroach allergens, in particular — contribute to asthma morbidity in disadvantaged urban children. Though that specific study is complete, it illustrates how asthma research often targets the communities most affected by the disease.
The landscape of asthma treatment is shifting faster than it has in decades. Biologics are rewriting the possibilities for severe disease. Smart inhalers with electronic monitoring are making adherence data more actionable. And trials like the one Eli Lilly is running on brenipatide for uncontrolled moderate-to-severe asthma — still recruiting as of mid-2026 — suggest that the pipeline of investigational therapies remains robust. For patients whose current treatment leaves them short of breath, literally and figuratively, the question is not whether clinical trials exist but which one might be the right fit.
研究の知恵